Is HLA-B58:01 genotyping cost effective in guiding allopurinol use in gout patients with chronic kid...
Is HLA-B58:01 genotyping cost effective in guiding allopurinol use in gout patients with chronic kidney disease?
About this item
Full title
Author / Creator
Publisher
England: Future Medicine Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: Future Medicine Ltd
Subjects
More information
Scope and Contents
Contents
Concerns for fatal severe cutaneous adverse reactions (SCARs) hamper allopurinol use.
We adopted a health system perspective to evaluate the cost–effectiveness of HLA-B*58:01 genotyping before allopurinol initiation. A decision tree compared three treatment strategies in gout patients with chronic kidney disease who have higher risk for SCAR. Th...
Alternative Titles
Full title
Is HLA-B58:01 genotyping cost effective in guiding allopurinol use in gout patients with chronic kidney disease?
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmed_primary_32180492
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmed_primary_32180492
Other Identifiers
ISSN
1462-2416
E-ISSN
1744-8042
DOI
10.2217/pgs-2019-0160
